Advanced search
Publication Cover
Acta Cardiologica Volume 69, 2014 - Issue 5
Submit an article Journal homepage
17
Views
3
CrossRef citations to date
0
Altmetric
Articles

How to choose between a pacemaker or defibrillator for resynchronization therapy?

Carl GillebertDept. of Cardiology, University Hospitals Leuven, Leuven, Belgium.
, MD,
Thomas MarynissenDept. of Cardiology, University Hospitals Leuven, Leuven, Belgium.
, MD,
Roel JanssenDept. of Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
, MD,
Walter DroogneDept. of Cardiology, University Hospitals Leuven, Leuven, Belgium.
, MD,
Gabor VorosDept. of Cardiology, University Hospitals Leuven, Leuven, Belgium.
, MD, PhD,
Christophe GarwegDept. of Cardiology, University Hospitals Leuven, Leuven, Belgium.
, MD &
Rik WillemsDept. of Cardiology, University Hospitals Leuven, Leuven, Belgium.;Dept. of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.Correspondence[email protected]
, MD, PhD show all
Pages 483-489 | Received 11 Jun 2014, Accepted 01 Jul 2014, Published online: 23 May 2017

References

  • Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation 2013; 128: 2407–18.
  • Bristow MR, Saxon LA, BoehmerJ, Krueger S. Kass DA, De Marco T, Carson P. DiCarlo L, DeM-ets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140–50.
  • Daubert JC, Leclercq C, Mabo P. Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator. Europace 2009 Nov; 11 Suppl 5: v87–92.
  • Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539–49.
  • Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization- Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27:1928–32.
  • Lam SK, Owen A. Combined resynchronisa-tion and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007; 335: 925.
  • Neyt M, Stroobandt 5, Obyn C, Camberlin C, Devriese 5, De Laet C, Van Brabandt H. Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. BMJ Open 2011; 1: e000276.
  • Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass DA, BoehmerJ, Singh 5, Whellan DJ, Carson P. Boscoe A, Baker TM, Gunderman MR. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2311–21.
  • Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P. Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE; ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach 5, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P. Lancellotti P. Linhart A, Nihoyannopoulos P. Piepoli MF, Ponikowski P. Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker 5; Document Reviewers, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bänsch D, Baumgartner H, Bsata W, Buser P. Charron P. Daubert JC, Dobreanu D, Faerestrand 5, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34:2281–329.
  • Lam SK, Tse HF, Lau CP. CRT begets CRT-D: is one better than the other? J Cardiovasc Electrophysiol 2008; 19: 1266–9.
  • Morani G, Gasparini M, Zanon F, Casali E, Spotti A, Reggiani A, Bertaglia E, Solimene F, Molon G, Accogli M, Tommasi C, Paoletti Perini A, Ciardiello C, Padeletti L. Cardiac resynchronization therapy-defibrillator improves long-term survival compared with cardiac resynchronization therapy-pacemaker in patients with a class IA indication for cardiac resynchronization therapy: data from the Contak Italian Registry. Europace 2013; 15: 1273–9.
  • Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S. Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008; 52:1834–43.
  • Gold MR, Daubert JC, Abraham WT, Hassager C, Dinerman JL, Hudnall JH, Cerkvenik J, Linde C. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol 2013; 6: 1163–8.
  • Bogale N, Priori 5, Cleland JG, Brugada J, Linde C, Auricchio A, van Veldhuisen DJ, Limbourg T, Gitt A, Gras D, Stellbrink C, Gasparini M, Metra M, Derumeaux G, Gadler F, Buga L, Dickstein K; Scientific Committee, National Coordinators, and Investigators. The European CRT Survey: 1 year (9-15 months) follow-up results. Eur J Heart Fail 2012; 14:61–73.
  • Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt 5, Andrews ML; MADIT-II Investigators. aRisk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 51:288–96.
  • Barsheshet A, Moss AJ, Huang DT, McNiff 5, Zareba W, Goldenberg I. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012; 59:2075–9.
  • Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, Maggioni AP, Anand I, Poole-Wilson PA, Fishbein DP, Johnson G, Anderson J, Mark DB, Bardy GH. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009; 120:835–42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.